AKT1 and cancer: Taken together, our findings show that Runx2 promotes cancer cell survival by directly inducing subunits of mTORC2 kinase complex of the Akt signaling pathway and further suggest Runx2 inhibition as a potential therapeutic strategy in combination with currently available PI3K/Akt/mTOR inhibitors.